The novel negative checkpoint regulator VISTA is expressed in gastric carcinoma and associated with PD-L1/PD-1: A future perspective for a combined gastric cancer therapy?

Oncoimmunology
Christine BögerChristoph Röcken

Abstract

A combined blockade of V-domain Ig suppressor of T-cell activation (VISTA) and PD-1 is a promising new cancer treatment option, which was efficient in murine tumor models and is currently tested in first phase I studies. Here, we analyzed the VISTA expression in a large and well-characterized gastric cancer (GC) cohort on 464 therapy-naive GC samples and 14 corresponding liver metastases using immunohistochemistry. Staining results were correlated with clinico-pathological characteristics, genetic alterations and survival. VISTA expression in tumor cells was detected in 41 GCs (8.8%) and 2 corresponding liver metastases (14.3%). Moreover, VISTA expression in immune cells was observed in 388 GCs (83.6%) and 6 liver metastases (42.9%). VISTA expression was associated with the Laurén phenotype, tumor localization, Epstein-Barr virus infection, KRAS- and PIK3CA-mutational status and PD-L1 expression. There was no significant correlation with patient outcome. Moreover, a change of VISTA expression in immune cells during tumor progression was observed. The co-incidence of VISTA and PD-L1 expression indicates a dual immune evasion mechanism of GC tumor cells and makes GC an interesting target for novel combined immune checkpoint inhib...Continue Reading

References

Mar 9, 2011·The Journal of Experimental Medicine·Li WangRandolph J Noelle
Nov 10, 2012·Annals of Oncology : Official Journal of the European Society for Medical Oncology·V S WarnekeC Röcken
Jul 13, 2013·Diagnostic Molecular Pathology : the American Journal of Surgical Pathology, Part B·Viktoria S WarnekeChristoph Röcken
Apr 3, 2014·Cancer Research·J Louise LinesRandolph Noelle
Apr 3, 2014·Cancer Research·Isabelle Le MercierLi Wang
Jun 5, 2014·Cancer Immunology Research·J Louise LinesRandolph Noelle
Aug 1, 2014·Nature·UNKNOWN Cancer Genome Atlas Research Network
Mar 4, 2015·Japanese Journal of Clinical Oncology·Ozge GumusaySuleyman Buyukberber
Mar 31, 2015·Seminars in Cancer Biology·Dass S VinayByoung S Kwon
May 13, 2015·Proceedings of the National Academy of Sciences of the United States of America·Jun LiuLi Wang
Jun 3, 2015·Histopathology·Marie-Luise MetzgerChristoph Röcken
Aug 8, 2015·Journal of Clinical Pathology·Christoph RöckenSandra Krüger
Sep 16, 2015·Applied Immunohistochemistry & Molecular Morphology : AIMM·Micaela MathiakChristoph Röcken
Dec 9, 2015·Pathology, Research and Practice·Christine BögerChristoph Röcken
Mar 25, 2016·Oncotarget·Christine BögerChristoph Röcken
Sep 27, 2016·Journal of Clinical Medicine·Emily F Goode, Elizabeth C Smyth
Nov 3, 2016·Cancer Immunology Research·Douglas B JohnsonChristine M Lovly
Oct 11, 2016·Scientific Reports·Patrícia OliveiraCarla Oliveira

❮ Previous
Next ❯

Citations

May 31, 2018·International Journal of Molecular Sciences·Riccardo DolcettiVincenzo Canzonieri
Jul 19, 2018·International Journal of Molecular Sciences·Irene GulloPatrícia Oliveira
May 8, 2019·Cancers·Sebastian ChrétienTheodoros Foukakis
Jun 4, 2019·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Katarzyna GuzikTad A Holak
Oct 28, 2019·Oncoimmunology·Tong LiElke Burgermeister
Sep 21, 2019·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·Stephanie MullerJennifer L Sauter
Jan 14, 2020·Clinical and Experimental Immunology·M A ElTanboulyJ L Lines
Aug 29, 2020·Journal of Molecular Medicine : Official Organ of the Gesellschaft Deutscher Naturforscher Und Ärzte·Malte BorggreweJon D Laman
Sep 1, 2018·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Pottayil G Sasikumar, Murali Ramachandra
Oct 31, 2019·Journal of Oncology·Lucía Figueroa-ProttiWarner Alpízar-Alpízar
Nov 30, 2019·Cancer Immunology, Immunotherapy : CII·Liju ZongYang Xiang
Jun 20, 2020·ESMO Open·Marco TagliamentoSilvia Novello
Aug 22, 2018·Cancer Immunology, Immunotherapy : CII·Shan XieLing Ni
Sep 1, 2018·World Journal of Gastroenterology : WJG·Daniela Cornelia LazărAdrian Goldiș
Nov 20, 2019·Journal of Cancer Research and Clinical Oncology·Franziska ClausenChristoph Röcken
Jul 1, 2020·Journal of Hematology & Oncology·Xing HuangTingbo Liang
Jul 17, 2018·Cancer Cell International·Francesca BattaglinHeinz-Josef Lenz
Apr 9, 2020·Cancer Immunology, Immunotherapy : CII·Liju ZongYang Xiang
Nov 26, 2020·Journal of Cancer Research and Clinical Oncology·Zelin HouHeguang Huang
Dec 29, 2020·Frontiers in Immunology·Hongbo ZhangLiang Shen
Feb 23, 2021·Naunyn-Schmiedeberg's Archives of Pharmacology·Oum Kaltoum Ait Boujmia
Apr 13, 2021·Frontiers in Immunology·Xiaoxue XieJun Liu
May 4, 2021·Frontiers in Oncology·Ji-Eun Irene Yum, Young-Kwon Hong
Jun 10, 2021·Communications Biology·Pottayil G SasikumarMurali Ramachandra
May 23, 2021·Pathology, Research and Practice·Saber MehdizadehMorteza Motallebnezhad
May 25, 2021·Frontiers in Pharmacology·Jii Bum LeeHye Ryun Kim
Jul 3, 2021·Cancers·Rita TerenzianiMara Bonelli
Jul 17, 2021·Frontiers in Oncology·Bonnie L RussellMonde Ntwasa

❮ Previous
Next ❯

Clinical Trials Mentioned

NCT02671955
NCT02812875

Software Mentioned

SPSS
VISTA

Related Concepts

Related Feeds

Cell Checkpoints & Regulators

Cell cycle checkpoints are a series of complex checkpoint mechanisms that detect DNA abnormalities and ensure that DNA replication and repair are complete before cell division. They are primarily regulated by cyclins, cyclin-dependent kinases, and the anaphase-promoting complex/cyclosome. Here is the latest research.